A new research study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) turns cancer scientists into molecular detectives, searching for clues for why certain cancers are able to spread and evolve by studying tissues collected within hours of death.
MD Anderson and the Broad Institute have launched a translational research platform to study rare cancers. The initiative will lead to a first-of-its-kind resource for the scientific community and will help to accelerate new therapies for patients with rare tumor types.
In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
MD Anderson and Innovent Biologics have announced a strategic collaboration agreement to co-develop Innovent’s anti-PD-1 monoclonal antibody for treating rare cancers in the U.S.
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers. Open-label Phase II study at MD Anderson reports on four cancer types.